Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nontransplant therapy for dialysis-related amyloidosis
Autore:
Copley, JB; Lindberg, JS;
Indirizzi:
Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Nephrol Sect, NewOrleans, LA 70121 USA Alton Ochsner Med Fdn & Ochsner Clin New Orleans LA USA 70121 A 70121 USA
Titolo Testata:
SEMINARS IN DIALYSIS
fascicolo: 2, volume: 14, anno: 2001,
pagine: 94 - 98
SICI:
0894-0959(200103)14:2<94:NTFDA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
CARPAL-TUNNEL SYNDROME; CHRONIC-HEMODIALYSIS PATIENTS; RESIDUAL RENAL-FUNCTION; GLYCATION END-PRODUCTS; LONG-TERM HEMODIALYSIS; BETA-2-MICROGLOBULIN AMYLOIDOSIS; DESTRUCTIVE SPONDYLOARTHROPATHY; BETA(2)-MICROGLOBULIN LEVELS; NOCTURNAL HEMODIALYSIS; PERITONEAL-DIALYSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
66
Recensione:
Indirizzi per estratti:
Indirizzo: Copley, JB Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Nephrol Sect, 1514 Jefferson Highway, New Orleans, LA 70121 USA Alton Ochsner MedFdn & Ochsner Clin 1514 Jefferson Highway New Orleans LA USA 70121
Citazione:
J.B. Copley e J.S. Lindberg, "Nontransplant therapy for dialysis-related amyloidosis", SEMIN DIAL, 14(2), 2001, pp. 94-98

Abstract

There is no specific treatment for dialysis-related amyloidosis (DRA). Available therapy is directed at removal of large quantities of beta (2)-microglobulin (beta M-2) and palliation of symptoms. Plasma concentrations of beta M-2 in end-stage renal disease (ESRD) depend on the degree of residual renal function, the type of blood purification therapy, and properties of the dialysis filtration membrane. Retention of beta M-2 appears to be a necessary, although not sufficient, condition for DRA. While preserving residualrenal function is important, dialysis modality largely determines beta M-2removal. Convective dialysis treatments (hemofiltration and hemodiafiltration) remove beta M-2 more efficiently than diffusive treatments (conventional dialysis). In addition, column adsorption of beta M-2 can extensively remove the molecule, as can nocturnal hemodialysis. Hemodialysis membrane properties that are particularly important with regard to beta M-2 removal include permeability, adsorptive capacity, and biocompatibility. As such, betaM-2 removal with highly permeable biocompatible membranes such as polysulfone and polyacrylonitrile is relatively large. Several studies have suggested that use of such membranes can significantly delay DRA development and may be useful in ameliorating DRA-associated symptoms. Non-dialysis-related therapy for DRA is palliative and includes both medical and surgical therapies. Medical therapy includes low-dose corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs). Surgical therapy consists of relief of carpal tunnel syndrome, or palliation of shoulder pain, destroyed weight-bearingjoints, or spinal cord compression. DRA is a serious complication of long-term dialysis. It is important for nephrologists to recognize the conditionand attempt to slow its progression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 19:48:05